vs

Side-by-side financial comparison of UNIVERSAL HEALTH REALTY INCOME TRUST (UHT) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $24.5M, roughly 1.1× UNIVERSAL HEALTH REALTY INCOME TRUST). UNIVERSAL HEALTH REALTY INCOME TRUST runs the higher net margin — 17.7% vs -71.0%, a 88.7% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -0.7%).

Universal Health Services, Inc. (UHS) is an American Fortune 500 company that provides hospital and healthcare services, based in King of Prussia, Pennsylvania. In 2024, UHS reported total revenues of $15.8 billion.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

UHT vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.1× larger
ZYME
$27.6M
$24.5M
UHT
Growing faster (revenue YoY)
ZYME
ZYME
+73.3% gap
ZYME
72.6%
-0.7%
UHT
Higher net margin
UHT
UHT
88.7% more per $
UHT
17.7%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
UHT
UHT
ZYME
ZYME
Revenue
$24.5M
$27.6M
Net Profit
$4.3M
$-19.6M
Gross Margin
Operating Margin
34.7%
-80.1%
Net Margin
17.7%
-71.0%
Revenue YoY
-0.7%
72.6%
Net Profit YoY
-7.2%
34.3%
EPS (diluted)
$0.32
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
UHT
UHT
ZYME
ZYME
Q4 25
$24.5M
Q3 25
$25.3M
$27.6M
Q2 25
$24.9M
$48.7M
Q1 25
$24.5M
$27.1M
Q4 24
$24.6M
$31.0M
Q3 24
$24.5M
$16.0M
Q2 24
$24.7M
$19.2M
Q1 24
$25.1M
$10.0M
Net Profit
UHT
UHT
ZYME
ZYME
Q4 25
$4.3M
Q3 25
$4.0M
$-19.6M
Q2 25
$4.5M
$2.3M
Q1 25
$4.8M
$-22.6M
Q4 24
$4.7M
$-23.5M
Q3 24
$4.0M
$-29.9M
Q2 24
$5.3M
$-37.7M
Q1 24
$5.3M
$-31.7M
Operating Margin
UHT
UHT
ZYME
ZYME
Q4 25
34.7%
Q3 25
33.2%
-80.1%
Q2 25
35.6%
-1.4%
Q1 25
36.8%
-94.5%
Q4 24
37.6%
-71.6%
Q3 24
34.7%
-213.8%
Q2 24
38.7%
-222.9%
Q1 24
37.6%
-376.9%
Net Margin
UHT
UHT
ZYME
ZYME
Q4 25
17.7%
Q3 25
15.9%
-71.0%
Q2 25
18.1%
4.8%
Q1 25
19.5%
-83.5%
Q4 24
18.9%
-75.8%
Q3 24
16.3%
-186.6%
Q2 24
21.3%
-195.8%
Q1 24
21.1%
-315.6%
EPS (diluted)
UHT
UHT
ZYME
ZYME
Q4 25
$0.32
Q3 25
$0.29
$-0.26
Q2 25
$0.32
$0.03
Q1 25
$0.34
$-0.30
Q4 24
$0.34
$-0.32
Q3 24
$0.29
$-0.39
Q2 24
$0.38
$-0.49
Q1 24
$0.38
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
UHT
UHT
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$6.7M
$64.8M
Total DebtLower is stronger
$374.8M
Stockholders' EquityBook value
$152.4M
$320.1M
Total Assets
$564.9M
$397.3M
Debt / EquityLower = less leverage
2.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
UHT
UHT
ZYME
ZYME
Q4 25
$6.7M
Q3 25
$6.9M
$64.8M
Q2 25
$6.6M
$98.3M
Q1 25
$7.0M
$76.2M
Q4 24
$7.1M
$66.1M
Q3 24
$6.4M
$122.4M
Q2 24
$5.6M
$71.0M
Q1 24
$7.7M
$114.8M
Total Debt
UHT
UHT
ZYME
ZYME
Q4 25
$374.8M
Q3 25
Q2 25
Q1 25
Q4 24
$368.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
UHT
UHT
ZYME
ZYME
Q4 25
$152.4M
Q3 25
$158.6M
$320.1M
Q2 25
$165.2M
$334.5M
Q1 25
$172.2M
$325.0M
Q4 24
$179.5M
$338.8M
Q3 24
$181.6M
$367.0M
Q2 24
$190.7M
$406.2M
Q1 24
$196.5M
$438.0M
Total Assets
UHT
UHT
ZYME
ZYME
Q4 25
$564.9M
Q3 25
$568.0M
$397.3M
Q2 25
$573.0M
$408.4M
Q1 25
$573.5M
$425.5M
Q4 24
$580.9M
$463.1M
Q3 24
$584.3M
$487.2M
Q2 24
$586.6M
$515.6M
Q1 24
$596.2M
$553.8M
Debt / Equity
UHT
UHT
ZYME
ZYME
Q4 25
2.46×
Q3 25
Q2 25
Q1 25
Q4 24
2.05×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
UHT
UHT
ZYME
ZYME
Operating Cash FlowLast quarter
$49.1M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
11.35×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
UHT
UHT
ZYME
ZYME
Q4 25
$49.1M
Q3 25
$10.2M
$-31.4M
Q2 25
$13.7M
$12.1M
Q1 25
$11.6M
$-3.4M
Q4 24
$46.9M
$-41.5M
Q3 24
$9.9M
$-5.9M
Q2 24
$12.1M
$-25.0M
Q1 24
$11.7M
$-37.7M
Free Cash Flow
UHT
UHT
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
UHT
UHT
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
UHT
UHT
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
UHT
UHT
ZYME
ZYME
Q4 25
11.35×
Q3 25
2.54×
Q2 25
3.05×
5.21×
Q1 25
2.43×
Q4 24
10.06×
Q3 24
2.48×
Q2 24
2.30×
Q1 24
2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

UHT
UHT

Reportable Segment Aggregation Before Other Operating Segment$23.1M94%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$2.3M9%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons